Anaphylaxis and Hypersensitivity Reactions

Anaphylaxis is a severe, rapidly developing, potentially life-threatening systemic hypersensitivity reaction that can, very rarely, follow vaccination. In immunization practice it is the prototypical serious immediate reaction: it is the basis of the classic absolute contraindication to a vaccine or its components, and it is a closely monitored adverse event with a standardized case definition. This entry describes what anaphylaxis is, how it is defined and recognized, and how often it occurs after vaccination.

Definition

Anaphylaxis is an acute, severe, generalized hypersensitivity reaction with rapid onset after exposure to a trigger, characteristically involving the skin or mucosa together with respiratory compromise, reduced blood pressure or associated end-organ dysfunction, or persistent severe gastrointestinal symptoms.

Scope

The entry covers the definition and recognition of anaphylaxis as an immediate (type I) hypersensitivity reaction, the standardized case definitions used in clinical practice and in immunization safety surveillance, the spectrum of milder hypersensitivity reactions, and the observed rates of anaphylaxis following vaccination. It treats anaphylaxis as a clinical entity for reference and evidence appraisal; it does not provide emergency management or dosing instructions, which follow current clinical guidelines.

Core questions

• How is anaphylaxis defined and distinguished from milder allergic reactions?
• What is the immunological mechanism of an immediate hypersensitivity reaction?
• How is anaphylaxis classified for immunization safety surveillance?
• How often does anaphylaxis occur after vaccination?

Key concepts

• Immediate (type I) hypersensitivity
• IgE-mediated mast cell and basophil activation
• NIAID/FAAN clinical criteria for anaphylaxis
• Brighton Collaboration case definition
• Allergy to a vaccine component
• Biphasic reaction
• Rate per million doses administered

Mechanisms

Anaphylaxis is most often an IgE-mediated immediate hypersensitivity reaction in which a sensitized individual re-exposed to an allergen triggers rapid activation and degranulation of mast cells and basophils, releasing histamine and other mediators that produce multisystem effects within minutes — urticaria and angioedema, bronchospasm and upper-airway swelling, and vasodilation with hypotension. Because the syndrome spans several organ systems and develops quickly, clinical criteria such as the NIAID/FAAN definition were established to recognize it consistently (sampson-2006), and for vaccine safety surveillance the Brighton Collaboration developed a graded case definition to classify reported events with defined levels of diagnostic certainty (ruggeberg-2007). Milder hypersensitivity reactions, such as isolated urticaria, lie on the same spectrum but do not meet the criteria for anaphylaxis.

Clinical relevance

Anaphylaxis after vaccination, although very rare, is the serious immediate reaction that underlies the classic absolute contraindication to a vaccine or one of its components, and its recognition is central to vaccine safety. This entry describes the entity and how it is defined and counted for surveillance; it is not a guide to emergency treatment or to determining eligibility, which are governed by current clinical guidelines and official immunization guidance (muraro-2014).

Epidemiology

Anaphylaxis following vaccination is rare. Large active-surveillance studies have estimated rates on the order of roughly one event per million vaccine doses across routine vaccines (mcneil-2016), and surveillance of mRNA COVID-19 vaccines early in their rollout likewise found anaphylaxis to be uncommon and to occur typically within a short interval after vaccination (shimabukuro-2021).

History

Anaphylaxis has been recognized clinically for over a century, but consensus diagnostic criteria were consolidated through the NIAID/FAAN symposia in the 2000s to standardize recognition (sampson-2006). In parallel, the Brighton Collaboration produced a harmonized case definition specifically for immunization safety so that anaphylaxis reported after vaccination could be classified comparably across systems (ruggeberg-2007). Subsequent large-scale surveillance quantified its rarity after routine vaccines (mcneil-2016) and after newer vaccine platforms (shimabukuro-2021).

Debates

Variation in case definitions

Differences between clinical and surveillance case definitions can affect which events are classified as anaphylaxis, which is why harmonized criteria such as the NIAID/FAAN and Brighton definitions were introduced to improve consistency.

Seminal works

• sampson-2006
• ruggeberg-2007
• mcneil-2016

Frequently asked questions

How common is anaphylaxis after vaccination?

It is rare; large surveillance studies have estimated rates on the order of about one event per million doses for routine vaccines, with reactions typically occurring soon after administration.

How is anaphylaxis different from a mild allergic reaction?

Anaphylaxis is a severe, rapidly evolving systemic reaction that usually involves more than one organ system (for example skin plus respiratory or cardiovascular compromise), whereas a mild allergic reaction such as isolated hives does not meet these criteria.